Bibliotecas PUC-SP - Busca Integrada

Neurotechnological Approaches to the Diagnosis and Treatment of Alzheimer’s Disease

Por Shen Ning, Shen Ning, Mehdi Jorfi, Mehdi Jorfi, Shaun R. Patel, Doo Yeon Kim, Rudolph E. Tanzi
Publicado no Frontiers in Neuroscience (2022-03-01)

The Impact of the Cellular Environment and Aging on Modeling Alzheimer's Disease in 3D Cell Culture Models

Por Matthias Hebisch, Stefanie Klostermeier, Katharina Wolf, Aldo R. Boccaccini, Stephan E. Wolf, Rudolph E. Tanzi, Doo Yeon Kim
Publicado no Advanced Science (2023-03-01)

Caspase-3-mediated cleavage of PHF-1 tau during apoptosis irrespective of excitotoxicity and oxidative stress: an implication to Alzheimer's disease

Por Hyo Jung Kang, Won Joo Yoon, Gyeong Joon Moon, Doo Yeon Kim, Seonghyang Sohn, Hyuk Jae Kwon, Byoung Joo Gwag
Publicado no Neurobiology of Disease (2005-04-01)

Blood–Brain Barrier Dysfunction in a 3D In Vitro Model of Alzheimer's Disease

Por Yoojin Shin, Se Hoon Choi, Eunhee Kim, Enjana Bylykbashi, Jeong Ah Kim, Seok Chung, Doo Yeon Kim, Roger D. Kamm, Rudolph E. Tanzi
Publicado no Advanced Science (2019-10-01)

Effects of Amyloid Beta (Aβ) Oligomers on Blood–Brain Barrier Using a 3D Microfluidic Vasculature-on-a-Chip Model

Por Samuel Chidiebere Uzoechi, Boyce Edwin Collins, Cody Joseph Badeaux, Yan Li, Sang Su Kwak, Doo Yeon Kim, Daniel Todd Laskowitz, Jin-Moo Lee, Yeoheung Yun
Publicado no Applied Sciences (2024-05-01)

Cryopreserving 3D cell culture models of Alzheimer’s disease in hydrogel microbeads

Por Jae Jung Kim, Matthias Hebisch, Sang Su Kwak, Monica Zheng, Shreya Nuli, Jun-Seok Bae, Emma Brand, Rudolph E. Tanzi, Daniel Irimia, Doo Yeon Kim
Publicado no Scientific Reports (2025-04-01)

Amyloid-β42/40 ratio drives tau pathology in 3D human neural cell culture models of Alzheimer’s disease

Por Sang Su Kwak, Kevin J. Washicosky, Emma Brand, Djuna von Maydell, Jenna Aronson, Susan Kim, Diane E. Capen, Murat Cetinbas, Ruslan Sadreyev, Shen Ning, Enjana Bylykbashi, Weiming Xia, Steven L. Wagner, Se Hoon Choi, Rudolph E. Tanzi, Doo Yeon Kim
Publicado no Nature Communications (2020-03-01)

Evaluation of bumetanide as a potential therapeutic agent for Alzheimer’s disease

Por Ben Boyarko, Sonia Podvin, Barry Greenberg, Jeremiah D. Momper, Yadong Huang, Yadong Huang, William H. Gerwick, William H. Gerwick, Anne G. Bang, Luisa Quinti, Ana Griciuc, Doo Yeon Kim, Rudolph E. Tanzi, Howard H. Feldman, Howard H. Feldman, Vivian Hook, Vivian Hook
Publicado no Frontiers in Pharmacology (2023-08-01)

Molecular hallmarks of excitatory and inhibitory neuronal resilience to Alzheimer’s disease

Por Isabel Castanho, Pourya Naderi Yeganeh, Carles A. Boix, Sarah L. Morgan, Hansruedi Mathys, Dmitry Prokopenko, Bartholomew White, Larisa M. Soto, Giulia Pegoraro, Saloni Shah, Athanasios Ploumakis, Nikolas Kalavros, David A. Bennett, Christoph Lange, Doo Yeon Kim, Lars Bertram, Li-Huei Tsai, Manolis Kellis, Rudolph E. Tanzi, Winston Hide
Publicado no Molecular Neurodegeneration (2025-10-01)

Protective Alzheimer's disease-associated APP A673T variant predominantly decreases sAPPβ levels in cerebrospinal fluid and 2D/3D cell culture models

Por Rebekka Wittrahm, Mari Takalo, Teemu Kuulasmaa, Petra M. Mäkinen, Petri Mäkinen, Saša Končarević, Vadim Fartzdinov, Stefan Selzer, Tarja Kokkola, Leila Antikainen, Henna Martiskainen, Susanna Kemppainen, Mikael Marttinen, Heli Jeskanen, Hannah Rostalski, Eija Rahunen, Miia Kivipelto, Tiia Ngandu, Teemu Natunen, Jean-Charles Lambert, Rudolph E. Tanzi, Doo Yeon Kim, Tuomas Rauramaa, Sanna-Kaisa Herukka, Hilkka Soininen, Markku Laakso, Ian Pike, Ville Leinonen, Annakaisa Haapasalo, Mikko Hiltunen
Publicado no Neurobiology of Disease (2023-06-01)